Jatin Shah

2021

In 2021, Jatin Shah earned a total compensation of $1.6M as Former Executive Vice President, Chief Medical Officer at Karyopharm Therapeutics.

Compensation breakdown

Non-Equity Incentive Plan$179,078
Option Awards$588,826
Salary$457,980
Stock Awards$320,509
Other$41,820
Total$1,588,213

Shah received $588.8K in option awards, accounting for 37% of the total pay in 2021.

Shah also received $179.1K in non-equity incentive plan, $458K in salary, $320.5K in stock awards and $41.8K in other compensation.

Rankings

In 2021, Jatin Shah's compensation ranked 7,011th out of 12,415 executives tracked by ExecPay. In other words, Shah earned more than 43.5% of executives.

ClassificationRankingPercentile
All
7,011
out of 12,415
44th
Division
Manufacturing
3,073
out of 5,505
44th
Major group
Chemicals And Allied Products
1,361
out of 2,375
43rd
Industry group
Drugs
1,212
out of 2,096
42nd
Industry
Pharmaceutical Preparations
884
out of 1,546
43rd
Source: SEC filing on April 8, 2022.

Shah's colleagues

We found five more compensation records of executives who worked with Jatin Shah at Karyopharm Therapeutics in 2021.

2021

Richard Paulson

Karyopharm Therapeutics

Chief Executive Officer

2021

Sharon Shacham

Karyopharm Therapeutics

Chief Scientific Officer

2021

Michael Kauffman

Karyopharm Therapeutics

Chief Executive Officer

2021

Michael Mason

Karyopharm Therapeutics

Chief Financial Officer

2021

Ran Frenkel

Karyopharm Therapeutics

Executive Vice President, Chief Development Officer

News

You may also like